Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with plaque psoriasis by a skin doctor (dermatologist)
- You are starting one of two specific medications for the first time: deucravacitinib or apremilast
- You are already signed up to a patient registry called the CorEvitas Psoriasis Registry and have agreed to allow your registry information to be used for research
Who may not be able to join:
- You are currently taking part in, or planning to join, another clinical trial that involves a treatment or intervention (note: being part of an observation-only study or registry does not count against you)
- You have taken deucravacitinib or apremilast before at any point in your treatment history, even if you stopped and are now restarting
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in body surface area (BSA); Investigator global assessment (IGA) response 0/1; Dermatology life quality index (DLQI) response 0/1; Time from date of treatment initiation to date of discontinuation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.